Medivation, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Medivation, Inc. in twelve months, the latest record being from 30 September 2016.
Since 2016, the database holds no purchases and 15 sales by insiders of the company.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
25 of 59 declarations
Medivation, Inc. is a biopharmaceutical company focused on developing treatments for cancer. It is listed on the NASDAQ under the symbol MDVN.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2015 | n.d. | 244.7 m USD | 1.47 USD | 10-K |
| Dec 2014 | n.d. | 276.5 m USD | 1.71 USD | 10-K |
| Dec 2013 | n.d. | -42.6 m USD | -0.28 USD | 10-K |
| Dec 2012 | n.d. | -41.3 m USD | -0.56 USD | 10-K |
| Dec 2011 | n.d. | -38.8 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.